vs
拉扎德（LAZ）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
拉扎德的季度营收约是Revvity的1.2倍（$929.4M vs $772.1M），Revvity净利率更高（12.7% vs 5.4%，领先7.4%），拉扎德同比增速更快（10.8% vs 5.9%），拉扎德自由现金流更多（$396.1M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 8.8%）
拉扎德公司是一家美国金融咨询与资产管理机构，业务覆盖投资银行、资产管理及其他金融服务，核心客户以机构客户为主。作为全球规模最大的独立投资银行，其主要行政办公室分布于纽约、巴黎及伦敦三地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LAZ vs RVTY — 直观对比
营收规模更大
LAZ
是对方的1.2倍
$772.1M
营收增速更快
LAZ
高出4.9%
5.9%
净利率更高
RVTY
高出7.4%
5.4%
自由现金流更多
LAZ
多$234.3M
$161.8M
两年增速更快
RVTY
近两年复合增速
8.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $929.4M | $772.1M |
| 净利润 | $49.9M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 9.1% | 14.5% |
| 净利率 | 5.4% | 12.7% |
| 营收同比 | 10.8% | 5.9% |
| 净利润同比 | -42.2% | 3.9% |
| 每股收益（稀释后） | $0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LAZRVTY
| Q4 25 | $929.4M | $772.1M | ||
| Q3 25 | $770.8M | $698.9M | ||
| Q2 25 | $817.2M | $720.3M | ||
| Q1 25 | $669.2M | $664.8M | ||
| Q4 24 | $839.0M | $729.4M | ||
| Q3 24 | $807.4M | $684.0M | ||
| Q2 24 | $708.0M | $691.7M | ||
| Q1 24 | $785.5M | $649.9M |
净利润LAZRVTY
| Q4 25 | $49.9M | $98.4M | ||
| Q3 25 | $71.2M | $46.7M | ||
| Q2 25 | $55.3M | $53.9M | ||
| Q1 25 | $60.4M | $42.2M | ||
| Q4 24 | $86.3M | $94.6M | ||
| Q3 24 | $107.9M | $94.4M | ||
| Q2 24 | $49.9M | $55.4M | ||
| Q1 24 | $35.8M | $26.0M |
毛利率LAZRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率LAZRVTY
| Q4 25 | 9.1% | 14.5% | ||
| Q3 25 | 12.3% | 11.7% | ||
| Q2 25 | 11.4% | 12.6% | ||
| Q1 25 | 8.2% | 10.9% | ||
| Q4 24 | 12.8% | 16.3% | ||
| Q3 24 | 20.0% | 14.3% | ||
| Q2 24 | 9.0% | 12.4% | ||
| Q1 24 | 6.9% | 6.8% |
净利率LAZRVTY
| Q4 25 | 5.4% | 12.7% | ||
| Q3 25 | 9.2% | 6.7% | ||
| Q2 25 | 6.8% | 7.5% | ||
| Q1 25 | 9.0% | 6.4% | ||
| Q4 24 | 10.3% | 13.0% | ||
| Q3 24 | 13.4% | 13.8% | ||
| Q2 24 | 7.0% | 8.0% | ||
| Q1 24 | 4.6% | 4.0% |
每股收益（稀释后）LAZRVTY
| Q4 25 | $0.44 | $0.86 | ||
| Q3 25 | $0.65 | $0.40 | ||
| Q2 25 | $0.52 | $0.46 | ||
| Q1 25 | $0.56 | $0.35 | ||
| Q4 24 | $0.82 | $0.77 | ||
| Q3 24 | $1.02 | $0.77 | ||
| Q2 24 | $0.49 | $0.45 | ||
| Q1 24 | $0.35 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $919.9M |
| 总债务越低越好 | $1.7B | — |
| 股东权益账面价值 | $873.7M | $7.3B |
| 总资产 | $4.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.93× | — |
8季度趋势，按日历期对齐
现金及短期投资LAZRVTY
| Q4 25 | $1.5B | $919.9M | ||
| Q3 25 | $1.2B | $931.4M | ||
| Q2 25 | $978.3M | $991.8M | ||
| Q1 25 | $908.6M | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $847.6M | $2.0B | ||
| Q1 24 | $923.2M | $1.7B |
总债务LAZRVTY
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
股东权益LAZRVTY
| Q4 25 | $873.7M | $7.3B | ||
| Q3 25 | $841.5M | $7.4B | ||
| Q2 25 | $741.6M | $7.6B | ||
| Q1 25 | $603.0M | $7.6B | ||
| Q4 24 | $636.2M | $7.7B | ||
| Q3 24 | $624.3M | $7.9B | ||
| Q2 24 | $458.7M | $7.9B | ||
| Q1 24 | $392.7M | $7.8B |
总资产LAZRVTY
| Q4 25 | $4.9B | $12.2B | ||
| Q3 25 | $4.6B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.2B | $12.4B | ||
| Q4 24 | $4.8B | $12.4B | ||
| Q3 24 | $4.8B | $12.8B | ||
| Q2 24 | $4.5B | $13.4B | ||
| Q1 24 | $4.6B | $13.4B |
负债/权益比LAZRVTY
| Q4 25 | 1.93× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.28× | — | ||
| Q1 25 | 2.80× | — | ||
| Q4 24 | 2.65× | — | ||
| Q3 24 | 2.97× | — | ||
| Q2 24 | 4.04× | — | ||
| Q1 24 | 4.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $399.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $396.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 42.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 8.02× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $487.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LAZRVTY
| Q4 25 | $399.7M | $182.0M | ||
| Q3 25 | $287.5M | $138.5M | ||
| Q2 25 | $49.7M | $134.3M | ||
| Q1 25 | $-217.5M | $128.2M | ||
| Q4 24 | $362.9M | $174.2M | ||
| Q3 24 | $293.7M | $147.9M | ||
| Q2 24 | $176.2M | $158.6M | ||
| Q1 24 | $-90.0M | $147.6M |
自由现金流LAZRVTY
| Q4 25 | $396.1M | $161.8M | ||
| Q3 25 | $284.6M | $120.0M | ||
| Q2 25 | $38.0M | $115.5M | ||
| Q1 25 | $-231.3M | $112.2M | ||
| Q4 24 | $348.0M | $149.8M | ||
| Q3 24 | $276.2M | $125.6M | ||
| Q2 24 | $169.8M | $136.6M | ||
| Q1 24 | $-96.6M | $129.7M |
自由现金流率LAZRVTY
| Q4 25 | 42.6% | 21.0% | ||
| Q3 25 | 36.9% | 17.2% | ||
| Q2 25 | 4.6% | 16.0% | ||
| Q1 25 | -34.6% | 16.9% | ||
| Q4 24 | 41.5% | 20.5% | ||
| Q3 24 | 34.2% | 18.4% | ||
| Q2 24 | 24.0% | 19.7% | ||
| Q1 24 | -12.3% | 20.0% |
资本支出强度LAZRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 2.1% | 2.4% | ||
| Q4 24 | 1.8% | 3.4% | ||
| Q3 24 | 2.2% | 3.3% | ||
| Q2 24 | 0.9% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率LAZRVTY
| Q4 25 | 8.02× | 1.85× | ||
| Q3 25 | 4.03× | 2.97× | ||
| Q2 25 | 0.90× | 2.49× | ||
| Q1 25 | -3.60× | 3.03× | ||
| Q4 24 | 4.20× | 1.84× | ||
| Q3 24 | 2.72× | 1.57× | ||
| Q2 24 | 3.53× | 2.87× | ||
| Q1 24 | -2.52× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAZ
| Financial Advisory Segment | $542.3M | 58% |
| Asset Management1 | $347.8M | 37% |
| Incentive Fees | $40.9M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
